Antitumor activity of various derivatives of 5-amino-4-imidazolecarboxamide was further examined.2', 3', 5'-Tri-
O-formyl-1-β-D-ribofuranosyl-5-formamido-4-imidazolethiocarboxamide (IV) was found to be quite active, and 1-β-D-ribofuranosyl-5-amino-4-imidazolethiocarboxamide 5'-phosphate was as active as the corresponding riboside, whereas thiocarbamoylamido, halogeno, and cyano derivatives of imidazole were totally inactive.
Antitumor activity and toxicity of IV were compared with those of the known active agents, 6-mercaptopurine and 9-β-D-ribofuranosyl-6-mercaptopurine. ED
90, LD
10, and therapeutic index of IV on the Nakahara-Fukuoka sarcoma system were 13, 160mg/kg/day, and 12.3, respectively, whereas they were 13, 100mg/kg/day, and 7.7 for 6-mercaptopurine, and 15, 370mg/kg/day, and 24.7 for 9-β-D-ribofuranosyl-6-mercaptopurine. Further, ILS
30, optimal dose, and therapeutic ratio of IV on the L-1210 leukemia system were 6.1, 50mg/kg/day, and 8.2, respectively, while they were 4.6, 30mg/kg/day, and 6.5 for 6-mercaptopurine, and 110, 300mg/kg/day, and 2.7 for 9-β-D-ribofuranosyl-6-mercaptopurine. As a result, IV was considered to be more potent than 6-mercaptopurine.
View full abstract